Finotonlimab

DB18859InvestigationalProtein Based Therapies

Finotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Immunoglobulin g4 (226-proline), anti-(human programmed cell death 1) (human-mus musculus monoclonal sct-i10a .gamma.4-chain), disulfide with human-mus musculus monoclonal sct-i10a .kappa.-chain, dimer
Code names: SCT-I10A

Resolves to

Compound

UNII533Z4G2286CAS2350298-85-8

Targets

Q15116PDCD1

What you can answer from here — as of September 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Finotonlimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account